These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1221134)
1. Inhibition of dopamine beta-hydroxylase in blood vessels by picolinic acid derivatives in vivo and their anthypertensive effects. Hidaka H; Shoka F; Hashizume Y; Takemoto N; Yamamoto M Jpn J Pharmacol; 1975 Oct; 25(5):515-24. PubMed ID: 1221134 [TBL] [Abstract][Full Text] [Related]
2. [Substituted picolinic acids as DBH inhibitors. Inhibition of dopamine beta-hydroxylase and antihypertensive action]. Piesche L; Hilse H; Oehlke J; Schrötter E; Oehme P Pharmazie; 1983 May; 38(5):335-8. PubMed ID: 6611632 [TBL] [Abstract][Full Text] [Related]
3. Effect of dopamine-beta-hydroxylase inhibitors on blood pressure and cardiac norepinephrine levels in rats subjected to immobilization stress. Ishii Y; Mimura C; Homma M J Pharmacol Exp Ther; 1976 Sep; 198(3):589-95. PubMed ID: 988175 [TBL] [Abstract][Full Text] [Related]
4. Effects of the novel dopamine beta-hydroxylase inhibitor SK&F 102698 on catecholamines and blood pressure in spontaneously hypertensive rats. Berkowitz BA; Arleth AJ; Sung CP; Kruse LI; DeWolf WE; Ohlstein EH J Pharmacol Exp Ther; 1988 Jun; 245(3):850-7. PubMed ID: 3385645 [TBL] [Abstract][Full Text] [Related]
5. [Effects of fusaric acid and its derivative on the cardiovascular system]. Furuta Y; Washizaki M Nihon Yakurigaku Zasshi; 1976 Mar; 72(2):139-44. PubMed ID: 987962 [TBL] [Abstract][Full Text] [Related]
6. SCH 10595, an effective dopamine- -hydroxylase inhibitor and a hypotensive agent. Korduba CA; Veals J; Wohl A; Symchowicz S; Tabachnick II J Pharmacol Exp Ther; 1973 Mar; 184(3):671-7. PubMed ID: 4687230 [No Abstract] [Full Text] [Related]
7. In vivo release of adrenal catecholamines in rats by fusaric acid. Racz K; Kuchel O; Buu NT Eur J Pharmacol; 1985 Feb; 109(1):1-7. PubMed ID: 3996464 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological action of FD-008, a new dopamine-beta-hydroxylase inhibitor. III. Effects on endogenous biogenic amine levels in rats. Ishii Y; Homma M; Yoshikawa A; Umezawa H Arzneimittelforschung; 1975 Mar; 25(3):383-5. PubMed ID: 1174036 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor. I. Effects on blood pressure in rats and dogs. Ishii Y; Fujii Y; Mimura Ch; Umezawa H Arzneimittelforschung; 1975 Jan; 25(1):55-9. PubMed ID: 1173769 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. Ohlstein EH; Kruse LI; Ezekiel M; Sherman SS; Erickson R; DeWolf WE; Berkowitz BA J Pharmacol Exp Ther; 1987 May; 241(2):554-9. PubMed ID: 3572812 [TBL] [Abstract][Full Text] [Related]
11. 24-hour rhythm of human plasma noradrenaline and the effect of fusaric acid, a dopamine-beta-hydroxylase inhibitor. Kato T; Hashimoto Y; Nagatsu T; Shinoda T; Okada T; Takeuchi T; Umezawa H Neuropsychobiology; 1980; 6(2):61-5. PubMed ID: 7354907 [TBL] [Abstract][Full Text] [Related]
12. [Antihypertensive effect of trifluoropentoxypicolinic acid: a pharmacokinetic study]. Horisaka K; Masuda S Nihon Yakurigaku Zasshi; 1984 Apr; 83(4):301-7. PubMed ID: 6745810 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of dopamine-induced stimulation of pancreatic secretion by 5-dimethyldithiocarbamylpicolinic acid (YP-279), a dopamine beta-hydroxylase inhibitor. Iwatsuki K; Hashimoto K Jpn J Pharmacol; 1979 Apr; 29(2):187-90. PubMed ID: 537244 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: a comparison with hydralazine. Velasco M; Gilbert CA; Rutledge CO; McNay JL Clin Pharmacol Ther; 1975 Aug; 18(2):145-53. PubMed ID: 1097150 [TBL] [Abstract][Full Text] [Related]
15. [Effect of dopamine on perfusion pressure in rat peripheral blood vessels]. Ozawa H; Aihara H; Sasajima M; Tanaka I Nihon Yakurigaku Zasshi; 1975 Jan; 71(1):61-9. PubMed ID: 1171813 [TBL] [Abstract][Full Text] [Related]
16. Effect of fusaric acid (a dopamine beta-hydroxylase inhibitor) on phaeochromocytoma. Nagasaka A; Hara I; Imai Y; Uchikawa T; Yamauchi K; Suzuki S; Takatsuki K; Tomita A; Niinomi M; Nakagawa H Clin Endocrinol (Oxf); 1985 Apr; 22(4):437-44. PubMed ID: 3987067 [TBL] [Abstract][Full Text] [Related]
17. Effects of fusaric (5-butylpicolinic) acid on the monosynaptic reflex neural activity of cat spinal cord. Watanabe Y; Matsumiya T; Oka T Tokai J Exp Clin Med; 1981 Oct; 6(4):443-51. PubMed ID: 7324082 [TBL] [Abstract][Full Text] [Related]
18. Plasma and lymph dopamine-beta-hydroxylase and norepinephrine during carotid occlusion. Velasquez MT; Alexander N Am J Physiol; 1979 Jan; 236(1):H96-100. PubMed ID: 434180 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of dopamine beta-hydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in vivo. Nagatsu T; Hidaka H; Kuzuya H; Takeya K; Umezawa H Biochem Pharmacol; 1970 Jan; 19(1):35-44. PubMed ID: 5507649 [No Abstract] [Full Text] [Related]
20. Fusaric acid-induced elevation of homovanillic acid in the CSF as an index of brain noradrenaline synthesis. Elghozi JL; Laude D; Chaouloff F Eur J Pharmacol; 1985 Nov; 117(3):363-7. PubMed ID: 4076351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]